Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWHK35)

• Drug Name: 2,3,4-trihydroxybenzoic acid Drug Info
• Synonyms: 2,3,4-TRIHYDROXYBENZOIC ACID; 610-02-6; 4-Pyrogallolcarboxylic acid; Pyrogallolcarboxylic acid; 2,3,4-Trihydroxybenzoate; Pyrogallol-4-carboxylic acid; UNII-AD1ID2JF5O; Benzoic acid, trihydroxy-; Benzoic acid, 2,3,4-trihydroxy-; 2,3,4-Trihydroxybenzene carboxylic acid; EINECS 210-205-9; NSC 27436; AD1ID2JF5O; BRN 2210807; CHEMBL220779; CHEBI:88714; 2,3,4-Trihydroxybenzoic acid, 97%; AK-94172; W-105210; pyrogallolcarboxylate; trihydroxybenzoic acid; 2,4-Trihydroxybenzoate; AC1L1YC0; 2,4-Trihydroxybenzoic acid; Oprea1_870375

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 11874
  ChEBI ID: CHEBI:88714
  CAS Number: CAS 610-02-6
  TTD Drug ID: DMWHK35

Molecule-Related Drug Atlas

Drug(s) Targeting P-selectin (SELP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizanlizumab	DMAHOVJ	Vaso-occlusive crisis	BE2Y	Approved	[2]
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[3]
Inclacumab	DMXV94M	Sickle-cell disorder	3A51	Phase 3	[4]
CY-1503	DML906E	Hypertension	BA00-BA04	Phase 2/3	[5]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[1]
SelG1	DMTQ2K0	Vaso-occlusive crisis	BE2Y	Phase 2	[6]
RPSGL-Ig	DM0BFJ5	Delayed graft function	4B24.0	Phase 2	[7]
PSI-697	DM75FWO	Atherosclerosis	BD40	Phase 1	[8]
CDP-850	DMWHQM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[9]
CY-1787	DMWY2NT	Allergy	4A80-4A85	Discontinued in Phase 1	[10]

Drug(s) Targeting L-selectin (SELL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GMI-1070	DMJ432G	Asthma	CA23	Phase 3	[3]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[1]
PURPUROGALLIN	DM63O4F	N. A.	N. A.	Terminated	[1]
Hu Dreg 55	DMK1VHF	Psoriasis vulgaris	EA90	Terminated	[11]
LD201t1	DMC5XQ6	Inflammation	1A00-CA43.1	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
L-selectin (SELL)	TT2IYXF	LYAM1_HUMAN	Inhibitor	[1]
P-selectin (SELP)	TTE5VG0	LYAM3_HUMAN	Inhibitor	[1]

References

• [1] Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
• [2] Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
• [3] Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
• [4] Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
• [5] Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
• [6] Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
• [7] rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
• [8] Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
• [9] WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
• [10] Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
• [11] Clinical pipeline report, company report or official report of glycomimetics.
• [12] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.